Skip to main content
. Author manuscript; available in PMC: 2020 May 19.
Published in final edited form as: J Med Primatol. 2019 Oct 1;49(1):26–33. doi: 10.1111/jmp.12438

Figure 4. BCL6 BTB inhibition via FX1 treatment did not cause any systemic adverse effect in rhesus macaques with lymphoid hyperplasia.

Figure 4.

(A) A schema for FX1 injection, blood collection, and lymph node biopsy sample collection in the study. (B) The frequency of immune response cells in the PBMC and lymph node were analyzed by flow cytometry and presented. (C) The frequency of T cell subsets [CD4+, CD8+, double positive (DP), double negative (DN)] in the PBMC and lymph node analyzed by flow cytometry were presented. (D) The body weight measured before and after FX1 treatment was presented. (E-F) The white blood cell counts (WBC) (E) and platelet (F) obtained by CBC analysis were presented. Note panel B lists color code for animal data shown in panels B-G.